Bringing the fundamentals into focus…
Back to Eli Lilly and Company
How Eli Lilly and Company stacks up
LLY · against 589 other Healthcare companies listed in US-listed
Valuation
50/ 100
Above the middle of the pack.
Ranked #185 of 590 · scores higher than 68% of peers
Bars: peers in each 10-point band of the valuation score50 peers with a valuation score of 50–59, including LLY · Click a bar to see the companies
Why valuation scores 50?
Weighted metrics compared with all Healthcare companies.Its metrics sit close to the Healthcare norm.
- EBITDA yield is close to the peer norm. EBITDA yield: 3.1% vs peer median 3.9%
- Earnings yield is close to the peer norm. Earnings yield: 2.4% vs peer median 1.4%
- Free cash flow yield is close to the peer norm. Free cash flow yield: 1.3% vs peer median 0.0%
Metric by metric
Position: dot = LLY, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | LLY | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 577 reported | 2.5% | -4.4% | 74% | 30% | |
| EBITDA yieldHigher is better · 578 reported | 3.8% | -1.2% | 64% | 50% | |
| Free cash flow yieldHigher is better · 553 reported | 1.3% | -2.2% | 63% | 20% | |
| Book yieldHigher is better · 582 reported | 3.2% | 26.1% | 14% | Context only |
Ranking by valuation score
Top 5 and the companies ranked around LLY| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 292M USD | 98 | 80 | |
| 2 | 2.0B USD | 97 | 97 | |
| 3 | 658M USD | 96 | 97 | |
| 3 | 567M USD | 96 | 81 | |
| 3 | 384M USD | 96 | 57 | |
| 183 | 10.2B USD | 51 | 36 | |
| 185 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score